Avec la création d’Initiative Pharma, Pierre Fabre s’engage en faveur de l’innovation et la souveraineté sanitaire Dans un contexte où la production de médicaments en France continue de décliner — seuls 9 % des nouveaux médicaments approuvés en Europe depuis 2020 y sont fabriqués — les Laboratoires Pierre Fabre participent à la création d’Initiative Pharma, un nouveau syndicat dédié à l’innovation thérapeutique et à la souveraineté sanitaire.
Laboratoires Pierre Fabre confirms the strength of its business model and is stepping up its investments in innovation and production • The company’s revenue totaled €3.2 billion, representing 4.6% growth compared to 2024 (at constant exchange rates). • Pharmaceutical revenue grew by 5.5%, reaching €1.4 billion and accounting for 44% of total revenue. • The Dermo-Cosmetics & Personal Care business grew by 3.9% to €1.7 billion, accounting for 55% of total revenue.
𝗪𝗲 𝗮𝗿𝗲 𝗽𝗿𝗼𝘂𝗱 𝘁𝗼 𝗶𝗻𝘁𝗿𝗼𝗱𝘂𝗰𝗲 𝘁𝗵𝗲 𝗪𝗲 𝗖𝗮𝗿𝗲 𝗠𝗼𝘃𝗲𝗺𝗲𝗻𝘁. At Laboratoires Pierre Fabre, care is at the heart of everything we do. Care is our driving force. Care is embedded in our daily actions and long-term ambitions. The 𝘞𝘦 𝘊𝘢𝘳𝘦 𝘔𝘰𝘷𝘦𝘮𝘦𝘯𝘵 is a collective commitment to care, collaboration, innovation and continuous progress built on four ways of caring: - 𝗖𝗼𝗻𝗾𝘂𝗲𝘀𝘁: Expanding our reach across 120 countries, driven by ambition and collaboration. - 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻: Advancing science with over €200 million invested in R&D to improve lives. - 𝗜𝗺𝗽𝗮𝗰𝘁: A purpose-driven company, with a humanitarian foundation as its majority shareholder, committed to providing access to healthcare to the most vulnerable populations in 21 countries across Africa and Asia. - 𝗣𝗿𝗼𝗴𝗿𝗲𝘀𝘀: Creating humanist, inclusive workplaces where everyone can grow and thrive. 𝘉𝘦𝘤𝘢𝘶𝘴𝘦 𝘦𝘷𝘦𝘳𝘺 𝘵𝘪𝘮𝘦 𝘸𝘦 𝘤𝘢𝘳𝘦 𝘧𝘰𝘳 𝘢 𝘴𝘪𝘯𝘨𝘭𝘦 𝘱𝘦𝘳𝘴𝘰𝘯, 𝘸𝘦 𝘮𝘢𝘬𝘦 𝘵𝘩𝘦 𝘸𝘰𝘳𝘭𝘥 𝘣𝘦𝘵𝘵𝘦𝘳. 𝗪𝗲. Because together, we are stronger. We are a team with a shared purpose. 𝗖𝗮𝗿𝗲. We care for our people and develop innovative solutions that improve lives. 𝗠𝗼𝘃𝗲𝗺𝗲𝗻𝘁. In a world that’s constantly evolving we move forward, together.
